The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2016 | Benefit of treating smouldering myeloma patients early with lenalidomide & dexamethasone
María-Victoria Mateos, MD, PhD from the University Hospital of Salamanca, Salamanca, Spain discusses the final results of a Phase III trial of lenalidomide plus dexamethasone versus no treatment in smouldering myeloma patients at high risk of progressing to multiple myeloma (MM) (NCT00480363). Dr Mateos explains that the first analysis of this trial was completed in 2013 and it showed a significant benefit in terms of time to progression and overall survival (OS). The results were now updated after a median follow-up of approximately 6 years. The analysis confirmed the significant benefit in terms of time to progression and OS when treating patients with lenalidomide plus dexamethasone compared to no treatment. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
